How many employees does ADMA Biologics, Inc. have?

ADMA Biologics, Inc. reported 647 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 25, 2026. That is down 5.5% from a year earlier.

What is ADMA Biologics, Inc.'s revenue per employee?

ADMA Biologics, Inc. brought in $510M of revenue in fiscal Dec 2025, which is $789K per employee. That ranks 16 of 39 companies we track in Biotechnology, where the median is $602K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

ADMA Biologics, Inc. employees and revenue per employee

ADMA · Biotechnology · $1.98B market cap

ADMA Biologics, Inc. had 647 employees at the end of fiscal Dec 2025, down 5.5% from a year earlier. Revenue for the year was $510M, up 19.6% from a year earlier, or $789K per employee. Revenue held up or grew while headcount stayed flat or fell.

Employees

647

-5.5% YoY

Revenue

$510M

+19.6% YoY

Revenue / employee

$789K

Peer median $602K

Rank in industry

16 of 39

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

ADMA employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	647	$510M	$789K	-5.5%	+19.6%
Dec 2024	685	$426M	$623K	+9.8%	+65.2%
Dec 2023	624	$258M	$414K	+1.1%	+67.6%
Dec 2022	617	$154M	$250K	+17.1%	+90.4%
Dec 2021	527	$80.9M	$154K	+29.8%	+91.7%
Dec 2020	406	$42.2M	$104K	+29.3%	+43.9%
Dec 2019	314	$29.3M	$93K	-1.3%	+72.8%
Dec 2018	318	$17.0M	$53K	+7.8%	-25.4%
Dec 2017	295	$22.8M	$77K	+220.7%	+113.5%
Dec 2016	92	$10.7M	$116K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

ADMA Biologics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
TGTX TG Therapeutics, Inc.	399	$616M	$1.54M	Efficient growth
KRYS Krystal Biotech, Inc.	295	$389M	$1.32M	Efficient growth
ARWR Arrowhead Pharmaceuticals, Inc.	711	$829M	$1.17M	Efficient growth
ADMA ADMA Biologics, Inc.	647	$510M	$789K	Leaner
AXSM Axsome Therapeutics, Inc.	925	$638M	$690K	Efficient growth
BBIO BridgeBio Pharma, Inc.	834	$502M	$602K	Efficient growth
TXG 10x Genomics, Inc.	1,178	$643M	$546K	Leaner
TWST Twist Bioscience Corporation	979	$377M	$385K	Efficient growth
INSM Insmed Incorporated	1,664	$606M	$364K	Efficient growth

Every Healthcare company

Questions about ADMA Biologics, Inc.

How many employees does ADMA Biologics, Inc. have?: ADMA Biologics, Inc. reported 647 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 25, 2026. That is down 5.5% from a year earlier.
What is ADMA Biologics, Inc.'s revenue per employee?: ADMA Biologics, Inc. brought in $510M of revenue in fiscal Dec 2025, which is $789K per employee. That ranks 16 of 39 companies we track in Biotechnology, where the median is $602K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare ADMA with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in ADMA Biologics, Inc.'s annual reports (Form 10-K), latest filed February 25, 2026. This is data, not a recommendation to buy or sell ADMA.